Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers found that the JAK1/2 inhibitor ruxolitinib helped normalize tissue-specific autoimmunity in APECED patients by reducing inflammation and immune cell accumulation, but it was also linked to subclinical side effects like anemia and weight gain.

This paper reviews adverse events related to hedgehog pathway inhibitors in advanced basal cell carcinoma patients, reporting no new clinical results but aiming to inform healthcare professionals for improved patient care.

This study developed the Alopecia Areata Investigator Global Assessment (AA-IGA) to measure scalp-hair loss in alopecia areata patients, incorporating perspectives of both patients and clinicians to define treatment success.

This study reported that five patients with alopecia areata achieved satisfactory results using 15 mg of Upadacitinib daily after conventional treatments had failed, without experiencing adverse events.

This case study observed that a patient with multiple refractory inflammatory conditions, including psoriasis, alopecia areata, and psoriatic arthritis, experienced significant improvements after three months of treatment with upadacitinib. The report suggests potential benefits of upadacitinib for similar conditions, recommending further clinical trials.

This review highlights that combination pharmacotherapy for androgenetic alopecia may offer enhanced hair growth efficacy and reduced side effects through distinct mechanisms, allowing for personalized treatment regimens that improve patient compliance and therapeutic outcomes.

This report reviews the clinical presentation and genetic aspects of a case of acrodermatitis enteropathica in a one-year-old child but provides no new clinical findings.

This study reported that androgenetic alopecia affects the psychosocial aspects and quality of life differently depending on marital status and occupational category, with married patients and professional workers experiencing higher emotional impact.

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

This article discusses the genetic and hormonal factors involved in androgenetic alopecia and its association with increased risks of cardiovascular diseases and metabolic disorders, but it does not present new research findings.

This study found that among men with androgenetic alopecia, the M-type pattern, either isolated or combined with others, was observed most frequently, using the BASP classification.

This article comments on previous studies linking severe androgenetic alopecia to increased vulnerability to COVID-19 and highlights ongoing research into antiandrogen therapies as potential treatments.

This study found that the alcoholic extract of Eclipta alba exhibited dose-dependent antianaphylactic effects in animal models, possibly due to membrane stabilization and reduced histamine release.

This case report highlights the importance of timely biochemical and radiographic evaluation of adrenal masses, as illustrated by a rapidly progressing aggressive adrenal cortical carcinoma.

This study found that intralesional Candida antigen was as effective as intralesional steroids for treating alopecia areata after 5 months, with significantly lower injection pain reported in the Candida group.

This study reported that the anti-γc antibody hC2 restored hair follicle homeostasis and suppressed hair loss in an AA-like mouse model by inhibiting autoreactive T-cell activity, suggesting that hC2 may offer a safer and more effective treatment for alopecia areata compared to current Jak inhibitors.

This study found a significant association between AGDAC measurements and the presence of PCOS, suggesting it could be an effective clinical tool in diagnosing the condition and its phenotypes, especially when combined with AMH.

This case report observed hair regrowth following the treatment of alopecia universalis and atopic dermatitis with tofacitinib, a JAK inhibitor.

This study investigated the mechanisms of Platycladi Cacumen in treating androgenetic alopecia, identifying potential key components and targets but found no specific targets or regulatory mechanisms.

This study found that Avicennia marina extract significantly increased hair growth in androgenic alopecia patients, suggesting its potential effectiveness by inhibiting 5 alpha-reductase and regulating relevant growth factors.

In this study, patients with varying severities of acne, seborrhoea, and hirsutism responded differently to Cyproteronacetate and Ethinyloestradiol treatment, with improvement rates dependent on symptom severity and treatment duration.

This study aims to evaluate the prevalence of androgenetic alopecia in transgender men undergoing testosterone therapy, noting that such hormone treatment can lead to dermatological issues that significantly affect their quality of life. Results are not reported in the abstract.

This retrospective case series reported that pediatric patients with alopecia totalis and subtotalis experienced significant hair regrowth after treatment with the JAK inhibitor upadacitinib, with mild acne as the most common side effect; however, larger studies are needed to establish its efficacy and safety conclusively.

This study highlights the importance of clinicians understanding the effects of gender-affirming hormones like testosterone, estrogen, and antiandrogens on hair growth, to effectively diagnose and treat androgenetic alopecia in gender minority patients.

Caffeine may protect hair follicles from stress-related hair loss.

This review discusses squaric acid dibutylester's use, effects, and safety in treating alopecia areata, but reports no new clinical results.

This source reviews clinical research progress on injection therapies for androgenetic alopecia, highlighting that methods like platelet derivatives, botulinum toxin, and stem cells may offer precise hair follicle targeting and reduced side effects compared to traditional treatments.

This study found that younger, unmarried individuals under 40, especially women, experienced significant anxiety and depression due to androgenetic alopecia, impacting their psychological well-being and self-perception.

This review found that recent innovations, such as topical medications, lasers, and microneedling, have shown significant reductions in androgenetic alopecia indicators, but more research is needed to refine treatments.

In this study, cepharanthine showed potent antiviral effects against tick-borne encephalitis virus in vitro by reducing viral replication and inflammation in human lung and neuroblastoma cells.